18 December 2017: Articles
Atypical Presentation of Radiation-Associated Breast Angiosarcoma: A Case Report and Review of Literature
Unusual clinical course, Unusual or unexpected effect of treatment
Yvette Farran BEF 1, Osvaldo Padilla AB 2, Karinn Chambers AD 3, Alexander Philipovskiy F 4*, Zeina Nahleh ADG 5DOI: 10.12659/AJCR.905157
Am J Case Rep 2017; 18:1347-1350
Abstract
BACKGROUND: Radiation-associated breast angiosarcoma is a rare clinical entity that is thought to be increasing in incidence.
CASE REPORT: Here we present the case of a 67-year-old female with a history of left breast invasive ductal carcinoma who received breast conserving surgery and radiation therapy eight years ago. She then presented with a painless mild skin discoloration of the left breast that had been present for over one year. Mammograms and ultrasounds were normal. A punch biopsy and a subsequent excisional biopsy revealed the diagnosis of angiosarcoma. The patient was treated with mastectomy and had no subsequent recurrences.
CONCLUSIONS: The long-term clinical surveillance for all patients who receive breast conservation surgery is recommended and a high degree of suspicion should be exercised in view of potential atypical presentations of this disease.
Keywords: Heavy Ion Radiotherapy, Hemangiosarcoma, Mastectomy
Background
Angiosarcoma is a rare vascular malignancy originating from endothelial cells (endoderm tumor) and can arise spontaneously or in association with factors like chronic lymphedema and radiation therapy. Most angiosarcomas develop in the skin or superficial soft tissue, while only 20% are in the deep soft tissues. Typical immunohistochemical expression profiles for angiosarcomas include upregulation of certain vascular-specific thyroxin kinase receptors, including,
Case Report
A 67-year-old Hispanic female with a past medical history of left breast invasive ductal carcinoma treated with lumpectomy, axillary lymph node dissection, and standard radiation therapy to the breast eight years ago, presented with a well circumscribed red skin discoloration with no additional skin changes or nodules in the left breast. Examination of the left breast revealed a flat 1 cm area of mild skin redness in the left lower quadrant of the breast without any palpable mass, warmth, or tenderness. The lesion was not associated with any edema, lesions, or blisters. Subsequent mammogram and ultrasound were negative for malignancy (BI-RADS-2). A punch biopsy demonstrated a vascular neoplasm with malignant cytological and histologic features (including nuclear pleomorphism, irregular nuclear contours, and invasion). Confirmatory immunohistochemistry stains were positive for endothelial marker (CD31, CD34, factor VIII), negative for pancytokeratin, ER, PR, HER2 and HHV8. A
Discussion
The incidence of radiation-induced angiosarcoma is low, ranging from 0.09 to 0.16% [7,8]. However, an increasing number of case reports are showing secondary angiosarcomas following radiation therapy, suggesting that the incidence is possibly on the rise [9]. In comparison, primary angiosarcomas account for 0.04% of all malignant breast tumors [10] constituting approximately 1 in 2,000 of primary breast cancers and typically occurring in young women in the third and fourth decades of life [11]. In contrast, secondary angiosarcomas are found in older women with a history of breast conservation therapy and radiation therapy since breast carcinoma commonly occurs in women between the ages of 55 and 69 years [11]. The average latency of secondary angiosarcoma of the breast following radiation therapy is around six years, with some studies reporting the occurrence of angiosarcoma as soon as 1–2 years after radiation and as late as 41 years after radiation [12–14]. Overall, the occurrence of breast angiosarcoma post-radiation appears to be shorter compared to radiation-induced sarcomas in general, which typically have a latency period of 10–12 years [14]. The odds ratio for women with a history of breast cancer for developing angiosarcoma in the chest or breast was found to be 11.6 in a retrospective case control study [15]. In one study, the relative risk of developing angiosarcoma following radiation therapy was found to be increased at a relative risk of 15.9, compared with a non-radiotherapy cohort and the largest increase in risk of angiosarcoma was noted in the chest wall and breast [16].
The association between radiation and angiosarcoma of the breast has been reported in the literature in various cohort studies [17]. Breast angiosarcoma is typically seen affecting the dermis within the radiation field making these angiosarcomas cutaneous in origin [7–12]. Cases of angiosarcoma developing in the breast parenchyma, arising from parenchymal vascular endothelial cells, have also been reported [8–11]. Radiation-associated angiosarcomas have distinct biological features. A study comparing the histopathology of sporadic angiosarcoma and radiation-associated angiosarcoma showed that radiation-associated angiosarcoma does not have overexpression of p53 and does not have a mutation in
Typically, a patient with angiosarcoma of the breast will present with a painless cutaneous lesion and blue-red skin discoloration resembling a hematoma [1,17]. It may be multifocal, typically involves a significant part of the breast, and is often associated with swelling, skin dimpling and thickening. The tumor size may vary and has been reported to range between 0.4 and 20 cm, with a mean tumor size of 7.5 cm [8]. In this case report, the clinical presentation was somewhat atypical as the tumor was small, not associated with edema or purple skin discoloration and showed low proliferation. However, despite being a low grade tumor, the characteristic
The diagnostic work-up for radiation-induced angiosarcoma includes imaging and biopsy. Imaging modalities include mammogram and ultrasound, but lesions can be occult on mammography, as was the case in this patient. MRIs are useful in defining disease extent but have low diagnostic sensitivity [10,11]. Incisional biopsy of the discolored skin and underlying mass is the most accurate and fastest way to obtain a diagnosis [10]. The hallmark findings of angiosarcoma microscopically are abnormal, pleomorphic, malignant endothelial cells. There may be well-differentiated areas, in which the endothelial cells form functioning vascular sinusoids that have areas of monocyte infiltration. In poorly differentiated areas, malignant endothelial cells form sheets of cells and have areas of hemorrhage and necrosis [20].
The treatment for angiosarcomas is surgical resection with mastectomy aiming at obtaining negative margins. Obtaining negative surgical margins is more important than the type of surgery, and the standard surgical procedure is mastectomy with negative margins [22]. However, studies following patients treated with radical surgery have noted that extensive recurrences can occur as soon as two months of surgery, and might occur in the chest wall flap [14].
The role of chemotherapy has not been clearly established. Most data came from retrospective case series studies or even case reports suggesting that angiosarcomas are relatively sensitive to taxanes and anthracyclines with initial overall response rate from 20% to 60% [23–26]. However, the relapse rate is high and overall survival is between 5 and 48 months [6,25]. A small study using hyperfractionated accelerated re-irradiation (HART) found that 79% of patients achieved disease control beyond the typical intervals to recurrence, suggesting that this treatment method may be more favorable than chemotherapy, however, it would be best to avoided in radiation-induced angiosarcomas [15].
Conclusions
In conclusion, this case illustrates an atypical presentation of radiation-associated secondary angiosarcoma, presenting with a small flat skin discoloration in the radiation field, not associated with a mass, edema, or other skin changes. Also, the tumor was low grade and was not detected on mammogram. A high level of suspicion should be exercised when patients who receive breast conservation surgery and radiation present with any skin discoloration. Continuous long-term surveillance and increasing both patient and physician awareness is also indicated.
References:
1.. Abbott R, Palmieri C, Angiosarcoma of the breast following surgery and radiotherapy for breast cancer: Nat Clin Prac Oncol, 2008; 5(12); 727-36
2.. Antonescu CR, Yoshida A, Guo T, KDR activating mutations human angiosarcoma are sensitive to specific kinase inhibitors: Cancer Res, 2009; 69(18); 7175-79, pmid: 19723655
3.. Guo T, Zhang L, Chang NE, Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions: Genes Chromosomes Cancer, 2011; 50(1); 25-33, pmid: 20949568
4.. Gladdy RA, Qin LX, Moraco N, Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas?: J Clin Oncol, 2010; 28(12); 2064-69, pmid: 20308666
5.. Budd GT, Management of angiosarcoma: Curr Oncol Rep, 2002; 4(6); 515-19, pmid: 12354365
6.. Perez-Ruiz E, Ribelles N, Sanchez-Muñoz A, Response to paclitaxel in a radiotherapy-induced breast angiosarcoma: Acta Oncol, 2009; 48(7); 1078-79, pmid: 19235566
7.. Lehnhardt M, Bohm J, Hirsch T, Radiation-induced angiosarcoma of the breast: Handchir Mikrochir Plast Chir, 2017; 49(2); 103-10, pmid: 28561170
8.. Glazebrook KN, Magut MJ, Reynolds C, Angiosarcoma of the breast: Am J Roentgenol, 2008; 190(2); 190-92
9.. Ito T, Tanaka K, Suzumura K, Angiosarcoma arising in the non-operated, sclerosing breast after primary irradiation, surviving 6 years post-resection: A case report and review of the Japanese literature: Int J Surg Case Rep, 2016; 24; 26-31, pmid: 27179333
10.. Zemanova M, Rauova K, Boljesikova E, Analysis of radiation-induced angiosarcoma of the breast: Bratisl Lek Listy, 2014; 115(5); 307-10, pmid: 25174061
11.. Yang WT, Hennessy BTJ, Dryden MJ, Mammary angiosarcomas: Imaging findings in 24 patients: Radiology, 2007; 242(3); 725-34, pmid: 17325063
12.. Hung J, Hiniker SM, Lucas DR, Sporadic versus radiation-associated angiosarcoma: A comparative clinicopathologic and molecular analysis of 48 cases.: Sarcom, 2013(9); 1-5
13.. Mery CM, George S, Bertagnolli MM, Raut CP, Secondary sarcomas after radiotherapy for breast cancer: Sustained risk and poor survival: Cancer, 2009; 15; 4055-63
14.. Feigenberg SJ, Price Mendenhall N, Reith JD, Angiosarcoma after breast-conserving therapy: Experience with hyperfractionated radiotherapy: Int J Radiat Oncol Biol Phys, 2002; 52(3); 620-26, pmid: 11849782
15.. Smith TL, Morris CG, Mendenhall NP, Angiosarcoma after breast-conserving therapy: Long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART): Acta Oncologica, 2014; 53(2); 235-41, pmid: 24345278
16.. Huang J, Mackillop WJ, Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma: Cancer, 2001; 1(92); 172-80
17.. Monroe AT, Feigenberg SJ, Mendenhall NP, Angiosarcoma after breast-conserving therapy: Cancer, 2003; 97(8); 1832-40, pmid: 12673708
18.. Huang SC, Zhang L, Sung YS, Recurrent CIC gene abnormalities in angiosarcomas: A molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations: Am J Surg Pathol, 2016; 40(5); 645-55, pmid: 26735859
19.. Manner J, Radlwimmer B, Hohenberger P, MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema: Am J Pathol, 2010; 176(1); 34-39, pmid: 20008140
20.. Young RJ, Brown NJ, Reed MW, Angiosarcoma: Lancet Oncol, 2010; 11(10); 983-91, pmid: 20537949
21.. Fraga-Guedes C, André S, Mastropasqua MG, Angiosarcoma and atypical vascular lesions of the breast: Diagnostic and prognostic role of MYC gene amplification and protein expression: Breast Cancer Res Treat, 2015; 151(1); 131-40, pmid: 25893585
22.. Lindford A, Bohling T, Vaalavirta L, Surgical management of radiation-associated cutaneous breast angiosarcoma: J Plast Reconstruct Aesthetic Surg, 2011; 64(8); 1036-42
23.. Penel N, Bui BN, Bay JO, Phase II trial of weekly paclitaxel for unrespectable angiosarcoma: The ANGIOTAX study: J Clin Oncol, 2008; 26(32); 5269-74, pmid: 18809609
24.. Mano MS, Fraser G, Kerr J, Radiation-induced angiosarcoma of breast shows major response to docetaxel after failure of anthracycline-based chemotherapy: Breast, 2006; 15(1); 117-18, pmid: 16473744
25.. Gambini D, Visintin R, Locatelli E, Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma: Tumori, 2009; 95(6); 828-31, pmid: 20210253
26.. Skubitz KM, Haddad PA, Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma: Cancer, 2005; 104(2); 361-66, pmid: 15948172
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






